Effects of semaglutide on pancreatic and hepatic fat content and islet β cell function in patients with type 2 diabetes mellitus combined with overweight and obesity
Objective To investigate the effects of semaglutide on blood glucose control,pancreatic and hepatic fat content,and islets β cell function in patients with type 2 diabetes mellitus(T2DM)combined with overweight and obesity.Methods A single-center,prospective,clinical case-control trial was adopted.Eighty-six patients diagnosed with T2DM combined with overweight(BMI 25-＜28 kg/m2)and obesity(BMI ≥ 28 kg/m2)in Jinhua Municipal Central Hospital from October 2021 to October 2022 were selected as the research subjects.All patients received a stable dose of metformin monotherapy or combined oral medication for at least 3 months,and the glycosylated hemoglobin(HbA1c)was 6.5％-8.0％.The patients were divided into the control group and the observation group by random number table method,with 43 cases in each group.The control group continued the original oral hypoglycemic regimen,while the observation group received semaglutide based on the original regimen(initial dose of 0.25 mg,increased to 0.5 mg after 4 weeks,administered subcutaneously once a week).Both groups were treated for 24 weeks.The fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPBG),HbA1C,total cholesterol(TC),triglyceride(TG),low-density lipoprotein(LDL),high-density lipoprotein(HDL),BMI and waist circumference(WC),fasting insulin(FINS),pancreatic islet β cell function index(HOMA-β)and insulin resistance index(HOMA-IR)were compared between the two groups.Pancreatic fat fraction(PFF)in the head,body,and tail of the pancreas was measured using an iterative decomposition of water and fat with echo asymmetry and least square estimation-iron quantification,the avearge PFF was calculated and compared between groups.Hepatic fat fraction(HFF)in the right upper,right lower,and left lobes of the liver was measured,and the avearge HFF was calculated and compared between groups.Results Thirty-nine patients in the control group and 40 patients in the observation group completed the study.After treatment,FPG,2 hPBG,HbA1C,BMI,FINS,HOMA-IR,average PFF and average HFF were significantly lower and HOMA-β was significantly higher in the observation group than those in the control group(all P＜0.01).Conclusion Semaglutide is convenient to apply and can further improve insulin and islet β cell function,reduce blood glucose levels,pancreatic and hepatic fat content for patients with T2DM combined with overweight and obesity on the basis of conventional hypoglycemic drugs,and at the same time can bring additional weight loss benefits.
万方数据
维普
